Although AI, machine learning, and quantum computing will someday improve our ability to forecast the future, for now Life Science Leader continues to seek knowledge from a cross section of life sciences industry execs.
With input from two long-time observers of the biopharma industry and its U.S. regulator, this article covers a cross-section of opinions regarding trends and proposals for improving the FDA review process.
Therapy designations and FDA approvals don’t mean much if the product can’t be manufactured at the level necessary to meet market demand. Here, a cross section of biopharma manufacturing executives offer their opinions on what to expect in biopharma manufacturing for 2020 and beyond.
Though the U.S. hasn’t witnessed a biosimilar market explosion as many anticipated, uptake has slowly but surely been creeping upward. I’m far from alone in believing it’s too early to propose dismantling the biosimilar industry.